The obesity drug developer has declared a new proposal from Novo “superior” to Pfizer’s original bid as well as an updated ...
The startup claims its medicines may be able to overcome the limitations of conventional antibody-drug conjugates by ...
While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear revenue misses,” wrote a Raymond James analyst.
Still, CEO Doug Ingram claimed removing the two drugs, Vyondys 53 and Amondys 45, from market would make “little sense” and ...
The deal hands Blackstone a piece of the potential future sales of an antibody-drug conjugate that could soon challenge marketed medicines from AstraZeneca and Gilead.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback